A recent Nurix Therapeutics Inc. patent describes proteolysis targeting chimeras (PROTACs) comprising a cereblon (CRBN) E3 ubiquitin ligase-binding moiety coupled to interleukin-1 receptor-associated kinase 4 (IRAK-4) targeting moiety via a linker reported to be useful for the treatment of cancer, metabolic diseases and inflammatory disorders.
Eureka Therapeutics Inc. has entered into a license agreement with the National Cancer Institute (NCI) to develop and commercialize a novel antibody targeting mesothelin (MSLN) in combination with Eureka's proprietary Artemis T-cell receptor platform.
Researchers from the University of Pittsburgh Medical Center and affiliated organizations aimed to validate a novel marker of duodenal neuroendocrine tumors (DNETs), NKK6.2.
Limited data exist on checkpoint inhibition that targets the early activation phase of adaptive immunity. B-and T-lymphocyte attenuator (BTLA) blockade is known to enhance and broaden CD8+ T-cell responses to a target antigen.
A new experimental drug, QN-302, has shown high antiproliferative activity in pancreatic cancer cells and antitumor activity in experimental pancreatic cancer models.
Zhejiang Medicine Co. Ltd.’s subsidiary, Novocodex Biopharmaceuticals Inc., reported positive phase III study results for its humanized anti-HER2 monoclonal antibody-drug conjugate, ARX-788, in the treatment of patients with HER2-positive locally advanced or metastatic breast cancer in China.
Les Laboratoires Servier SAS is touting its phase III win with vorasidenib as the first major advance in decades for low-grade glioma, with the trial called Indigo scoring statistical significance on two measures against residual or recurrent isocitrate dehydrogenase-mutant disease. The Suresnes, France-based firm said Indigo met the primary endpoint of progression-free survival (PFS) and the key secondary endpoint of time to next intervention (TTNI). The results of the prespecified interim analysis proved not only statistically significant but also clinically meaningful in PFS and TTNI.
China’s NMPA approved Shanghai Shengdi Pharmaceutical Co. Ltd.’s adebrelimab (SHR-1316) for first-line treatment of extensive-stage small-cell lung cancer (ES-SCLC) in combination with chemotherapy. The approval in mainland China makes adebrelimab the third domestic PD-L1 monoclonal antibody to make it to the domestic market. Shanghai Shengdi is a subsidiary of Jiangsu Hengrui Medicine Co. Ltd.
RSS
